5-heteroaryl substituted indazoles as kinase inhibitors

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibitin...

Full description

Saved in:
Bibliographic Details
Main Authors BIQIN LI, MELISSA J. MICHMERHUIZEN, NIGEL ST. JOHN MOORE, NICOLE TEUSCH, ANIL VASUDEVAN, DAWN GEORGE, ERIC T. JOHNSON, ALAN F. GASIECKI, KATHY SARRIS, JYOTI R. PATEL, VIJAYA J. GRACIAS, LU WANG, DOUGLAS M. KALVIN, HELMUT MACK, BRIAN D. WAKEFIELD, ADRIAN HOBSON, SEAN C. TURNER, ANDREW J. LONG, MARGARETHA BAKKER, PETER J. KOVAR, IRINI AKRITOPOULOU-ZANZE, STEVAN W. DJURIC, QI SHUAI, KRISTINE FRANK
Format Patent
LanguageEnglish
Published 18.12.2008
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
Bibliography:Application Number: AU20080262038